C-Erb-2 gene amplification and chromosomal anomalies in bladder cancer: Preliminary results

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 4, 2005, Pages 633-638

  Leonardo, Costantino ^a,c   Merola, R ^b   Orlandi, G ^b   Leonardo, F ^a   Rondoni, M ^a   De Nunzio, C ^a  

^a Leopoldo Parodi Delfino Hospital   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c NONE   (Italy)

Author keywords

Aneusomy; Bladder cancer; c erB 2; HER 2 neu; Oncogenes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; ANEUSOMY; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER TUMOR; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CHROMOSOME 17; CHROMOSOME 7; CHROMOSOME 9; CHROMOSOME ABERRATION; CLINICAL ARTICLE; GENE AMPLIFICATION; HEREDITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ONCOGENE; ONCOGENE C ERB 2; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CHROMOSOME ABERRATIONS; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; URINARY BLADDER NEOPLASMS;

EID: 31344455059     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Greenlee R.T., Murray T., Bolden S. et al.: Cancer statistics, 2000. Cancer J. Clin. 50: 7-33, 2000.
2. Jakse G., Loindi W., Seeber G.: Stage T1 grade 3 transitional cell carcinoma of the bladder: an unfavourable tumor? J. Urol. 137: 39-43, 1987.
3. Cianciulli A.M., Leonardo C., Coletta A.M., Marzano R., Iori F., De Nunzio C., Franco G., Merola R., Laurenti C.: Genetic instability in superficial bladder cancer and adjacent mucosa: an interphase cytogenetic study. Human Pathol. 34: 214-221, 2003.
4. Knowles M.A.: The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int. 84: 412-427, 2003.
5. Hovey R.M., Chu L., Balazs M. et al.: Genetic alterations in primary bladder cancers and their metastases. Cancer Res. 58: 3555-3560, 1998.
6. Coussens L., Yang-Feng T.L., Liao Y.C. et al.: Tyrosine Kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139, 1985.
7. Press M.F., Bernstein L., Thomas P.A., Meisner L.F., Zhou J.Y., Ma Y. et al.: Her2/neu gene amplification characterised by fluorescence in situ hybridisation: poor prognosis in node negative breast carcinomas. J. Clin. Oncol. 11: 1936-1942, 1993.
8. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wwong S.G., Keith D.E., Levin W.J. et al.: Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
9. Moriyama M., Akiyama T., Yamamoto T., Kawamoto T., Kato T., Sato K., Watanuki T., Hikage T., Katsut and Mori S.: Expression of cerb2 gene product in urinary bladder cancer. J. Urol. 145: 423-427, 1991.
10. Mellon J.K., Lunec J., Wrigh C., Horne C.H.W., Kelly P. and Neal D.: CERB 2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J. Urol. 155: 321-326, 1996.
11. Tetu B., Fradet Y., Allrd P., Veilleux C., Roberge N. and Bernard P.: Prevalence and clinical significance of HER2/neu, p53 and Rb expression in primary superficial bladder cancer. J. Urol. 155: 1784-1788, 1996.
12. Ohta J., Miyosh Y., Uemura H., Fujinami K. et al.: Fluorescence in situ hybridisation evaluation of cerb2 gene amplification and chromosomal anomalies in bladder cancer. Clin. Cancer Res. 7: 2463-2467, 2001.
13. Cianciulli A.M., Botti C., Coletta A.M., Buglioni S., Marzano R., Benevolo M., Cione A., Mottolese M.: Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of Her 2 in breast cancer. Cancer Genet. and Cytogenet. 133: 66-71, 2002.
14. Waldman F.M., Caroll P.R., Kerschmann R., Cohen M.B., Field F.G., Mayall B.H.: Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res. 51:3807-3813, 1991.
15. Spruck C.H.III., Ohneseit P.F., Gonzales Zulueta M.: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54: 784-788, 1994.
16. Li B., Kanamaru H., Noriki S., Fukuda M., Okada K.: Numeric aberration of chromosome 17 is strongly correlated with p53 overexpression, tumor proliferation and histopathology in human bladder cancer. Int. J. Urol. 5: 317, 1998.
17. Epstein J.I., Amin M.B., Reuter V.R. et al.: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder consensus conference committee. Am. J. Surg. Pathol. 22: 1435-1448, 1998.
18. UICC. TNM classification of malignant tumors, 6th Ed. New York: Wiley-Liss, 2002.
19. Wood D.P. jr, Wartinger D.D., Reuter V. et al.: DNA, RNA and and immunohistochemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder. J. Urol. 146: 1398-1401, 1991.
20. Elledge RM., Green S., Ciocca D. et al.: Her 2 expression and response to tamoxifene an estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin. Cancer Res. 4: 7-12, 1998.
21. Pauletti G., Dandekar S., Rong H.M., Ramos L., Peng H.J., Seshandri R., Slamon D.J.: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J. Clin. Oncol. 18: 3651-3664, 2000.
22. Sauter G., Moch H., Moore D., Carroll P. et al.: Heterogeneity of erb-2 gene amplification in bladder cancer. Cancer Res. 53 (suppl): 2199-2203, 1993.
23. Miyamoto H., Kubota Y., Noguchi S., Takase K., Matsuzaki J., Moriyma M., Takebayashi S., Kitamura H. and Hosaka M.: c-ERB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 55: 679-683, 2000.
24. Jimenez R.F., Hussain M., Bianco F.J., Vaishampayan U., Tabazcka P., Sakr W.A., Pontes J.E., Wood J., Grignon D.J.: Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumor. Clin. Cancer Res. 7: 2440-2447, 2001.